Johnson & Johnson shares fall after company beats on earnings and revenue, but lowers pharmaceutical sales guidance
J&J, whose financial results are considered a bellwether for many health companies, said its first-quarter sales grew 5.6% over the same quarter last year.
J&J, whose financial results are considered a bellwether for many health companies, said its first-quarter sales grew 5.6% over the same quarter last year.
